|Bid||6.56 x 2200|
|Ask||6.70 x 1800|
|Day's Range||6.42 - 6.72|
|52 Week Range||3.26 - 8.87|
|Beta (5Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.79|
Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 2020. The conference, which will take place November 16-18, 2020, is being conducted with a virtual format.
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update VK0214 Phase 1 Trial Initiated In September 2020, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced the initiation of a Phase 1 clinical trial of VK0214, the company’s second thyroid beta (TRβ) receptor agonist. It is a randomized, double blind, placebo controlled, single ascending dose (SAD) and multiple ascending